Baker Institute

Star Mountain Capital Adds Former Dallas Fed CEO, Goldman Sachs Vice Chairman, Robert Kaplan, as Senior Advisor

Retrieved on: 
Tuesday, February 13, 2024

Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.

Key Points: 
  • Star Mountain Capital , LLC (“Star Mountain”), a rapidly growing specialized private credit and secondaries investment firm targeting systematic alpha and low market correlated returns for its global institutional and high-net-worth investors is pleased to announce that Robert Kaplan has joined as Senior Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240213968210/en/
    Robert S. Kaplan, Star Mountain Capital Senior Advisor (Photo: Business Wire)
    Robert Kaplan has over 40 years of investment management, business management, monetary policy, investment banking, and leadership experience.
  • His previous positions include CEO and President of the Federal Reserve Bank of Dallas, Vice Chairman of Investment Banking and Investment Management Divisions of Goldman Sachs, and Professor and Senior Associate Dean of Harvard Business School.
  • “We are honored to have Rob join Star Mountain as an aligned Senior Advisor bringing extensive investment, strategic leadership, business management and governance experience,” said Brett Hickey , Star Mountain Capital Founder & CEO.

New Data Added to NASHP's Hospital Cost Tool

Retrieved on: 
Tuesday, January 9, 2024

WASHINGTON, Jan. 9, 2024 /PRNewswire/ -- The National Academy for State Health Policy (NASHP) released an update to its Hospital Cost Tool to include 2022 data and new metrics on hospital labor expenses. As a result, users of this publicly available tool can access data on hospital costs such as operating profit margins, cost to charge ratios, breakeven points, and more for approximately 4,600 hospitals for 2011 through 2022.

Key Points: 
  • WASHINGTON, Jan. 9, 2024 /PRNewswire/ -- The National Academy for State Health Policy (NASHP) released an update to its Hospital Cost Tool to include 2022 data and new metrics on hospital labor expenses.
  • States are actively using the Hospital Cost Tool to inform state policymaking efforts:
    Texas Employers for Affordable Healthcare , a coalition of interested parties, used Texas hospital cost data from the NASHP tool to create a state specific dashboard that shares information by legislative districts.
  • "The Hospital Cost Tool provides unprecedented insights into hospital operating costs and financial performance," said Acting Health Insurance Commissioner Cory King.
  • The Hospital Cost Tool uses annual Medicare Cost Reports that have been completed and attested to by hospital staff, then submitted to the federal government and posted to the Healthcare Cost Report Information System (HCRIS) database.

Future Minerals Forum Advances Global Discussion on Clean Energy Transition

Retrieved on: 
Tuesday, December 26, 2023

RIYADH, Saudi Arabia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Future Minerals Forum (FMF), scheduled to take place 9-11 January in Riyadh, Saudi Arabia, today announced three new strategic partnerships to inform the global discourse on minerals and their critical role in sustainable global development and the need to transition to new energy sources.

Key Points: 
  • RIYADH, Saudi Arabia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Future Minerals Forum (FMF), scheduled to take place 9-11 January in Riyadh, Saudi Arabia, today announced three new strategic partnerships to inform the global discourse on minerals and their critical role in sustainable global development and the need to transition to new energy sources.
  • They complement existing partnerships with McKinsey & Company, Payne Institute for Public Policy, Clareo-DPI and Baker Institute.
  • The white paper will identify key drivers for the creation of sustainable value chains as well as highlight the current challenges facing the global minerals and how they affect the minerals industry across this resource-rich area.
  • Global AI is set to conduct a comprehensive global sentiment analysis using state-of-the-art artificial intelligence, focusing on mining and mineral operations across the Super Region.

Is it a healthy day in the neighborhood? Louisville institutions partner in Universal Basic Neighborhood research

Retrieved on: 
Friday, July 28, 2023

LOUISVILLE, Ky., July 28, 2023 /PRNewswire-PRWeb/ -- What characteristics of a neighborhood contribute to the health of its residents – or reduce it?

Key Points: 
  • LOUISVILLE, Ky., July 28, 2023 /PRNewswire-PRWeb/ -- What characteristics of a neighborhood contribute to the health of its residents – or reduce it?
  • A universal basic neighborhood is one that has all the necessary community assets that help residents thrive in their place.
  • For example, in Louisville's predominantly Black communities, life expectancy is as much as 12.6 years less than in the most affluent, predominantly white communities.
  • Black babies born from 2011-2015 have a death rate 1.95 times higher than the Louisville Metro average and 2.31 times higher than white babies.

Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors

Retrieved on: 
Monday, July 17, 2023

EATONTOWN, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a healthcare technology company commercializing the first and only FDA-approved heart attack warning system to improve long-term management and outcomes of high-risk coronary disease in patients, announced today that Professor Ian Meredith AM, has agreed to join the Company’s Board of Directors following the closing of the Company’s previously announced business combination with BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) (“BIOS”) (Nasdaq: BIOS), a special purpose acquisition company. Professor Meredith recently retired from Boston Scientific after serving over six years as its Executive Vice President and Global Chief Medical Officer, where he was responsible for global leadership of medical, clinical science and trial strategy across the organization. Prior to joining Boston Scientific, Professor Meredith served for 12 years as a professor and director of MonashHeart, an internationally recognized cardiology service within Monash Health—and today serves as an Honorary Professor of Medicine and Cardiology at Monash University in Melbourne, Australia.

Key Points: 
  • As an Avertix board member, Professor Meredith will bring his decades long experience as a leading interventional cardiologist and thought leadership to Avertix.
  • “We believe Professor Meredith is one of the world’s most eminent clinicians in both acute cardiac care and clinical investigations,” said Ross Haghighat, Executive Chairman of Avertix.
  • “Avertix has a meaningful product that holds the potential to empower patients at a time of great anxiety and uncertainty in their lives,” said Professor Meredith.
  • Upon completion of the Transaction, the combined company’s securities are expected to be listed on Nasdaq under the ticker symbol “AVRT.”

Industry leaders to speak at Wood Mackenzie’s Energy & Natural Resources Summit: Americas 2022

Retrieved on: 
Wednesday, October 12, 2022

Join Wood Mackenzies expert analysts as well as leaders from across the energy and natural resources industries to hear how companies, investors and governments can succeed in this rapidly changing world, through the current crisis and beyond at the Energy & Natural Resources Summit: Americas 2022 in Houston on November 3.

Key Points: 
  • Join Wood Mackenzies expert analysts as well as leaders from across the energy and natural resources industries to hear how companies, investors and governments can succeed in this rapidly changing world, through the current crisis and beyond at the Energy & Natural Resources Summit: Americas 2022 in Houston on November 3.
  • Key themes on the agenda include:
    What Does New Geopolitical Order Mean for Energy and Natural Resources?
  • The Energy & Natural Resources Summit will hear from leading experts from across the industry.
  • For further information about the Energy & Natural Resources Summit please contact our events team: [email protected]

Topl Raises $15M Series A Funding Led by Mercury, Republic Asia and Cryptology

Retrieved on: 
Tuesday, July 26, 2022

Topl has helped to track and monetize a variety of products across the globe, including conflict free diamonds, ethically sourced coffee, and fair-wage cocoa.

Key Points: 
  • Topl has helped to track and monetize a variety of products across the globe, including conflict free diamonds, ethically sourced coffee, and fair-wage cocoa.
  • Republic Asia, a division of Republic focusing on Asia-related FinTech/web3 solutions, will be joining the Topl board and assist with international expansion.
  • In addition to funding, grant recipients will receive development, go-to-market, and fundraising support from Topl and its network of investors, partnerships, and academics.
  • The company offers a Blockchain-as-a-Service (BaaS) solution , allowing its users and technology partners two clicks to gain off-the-shelf access to the Topl Blockchain.

Rapidan Energy Group Founder and President Bob McNally Welcomes Clay Seigle as Rapidan's New Global Oil Service Director

Retrieved on: 
Friday, July 15, 2022

WASHINGTON, July 15, 2022 /PRNewswire/ -- Statement from Bob McNally, Founder and President of Rapidan Energy Group:

Key Points: 
  • WASHINGTON, July 15, 2022 /PRNewswire/ -- Statement from Bob McNally, Founder and President of Rapidan Energy Group:
    Clay brings 23 years' experience in the energy industry.
  • Previously, he was Energy Segment Lead at Maxar and served in several roles at IHS, including Director of its Global Oil Service.
  • Prior to IHS, Clay was Senior Oil Market Analyst at Enron and an Analyst at the US Department of Energy.
  • We help leading corporations and financial market participants identify opportunities and manage risks in the global energy industry and markets.

REDUCE LAP-HF II ANALYSES SHOW 50% OF STUDY PATIENTS DEMONSTRATED SIGNIFICANT CLINICAL BENEFIT FROM THE CORVIA® ATRIAL SHUNT

Retrieved on: 
Friday, April 1, 2022

TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. In a large responder population, representing 50% of study patients, treatment with the Corvia® Atrial Shunt resulted in a 45% reduction in HF events and a 55% greater improvement in quality of life compared to sham control. Additionally, these data offer essential new insights into the role of exercise in accurately predicting patients who may or may not benefit from this novel therapy. The analyses were published online in Circulation1

Key Points: 
  • The analyses were published online in Circulation1
    "We are extremely encouraged by these analyses from the REDUCE LAP-HF II trial.
  • The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor of HF symptoms in HFpEF patients.
  • The REDUCE LAP-HF II trial randomized 626 patients at 89 centers across the US, Canada, Europe, Australia, and Japan.
  • "The Corvia Atrial Shunt is the most rigorously studied atrial shunt therapy.

REDUCE LAP-HF II ANALYSES SHOW 50% OF STUDY PATIENTS DEMONSTRATED SIGNIFICANT CLINICAL BENEFIT FROM THE CORVIA® ATRIAL SHUNT

Retrieved on: 
Friday, April 1, 2022

TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. In a large responder population, representing 50% of study patients, treatment with the Corvia® Atrial Shunt resulted in a 45% reduction in HF events and a 55% greater improvement in quality of life compared to sham control. Additionally, these data offer essential new insights into the role of exercise in accurately predicting patients who may or may not benefit from this novel therapy. The analyses were published online in Circulation1

Key Points: 
  • The analyses were published online in Circulation1
    "We are extremely encouraged by these analyses from the REDUCE LAP-HF II trial.
  • The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor of HF symptoms in HFpEF patients.
  • The REDUCE LAP-HF II trial randomized 626 patients at 89 centers across the US, Canada, Europe, Australia, and Japan.
  • "The Corvia Atrial Shunt is the most rigorously studied atrial shunt therapy.